BioCentury

Concentra's deal for iTeos is at least the sixth acquisition the firm has made since April, providing an off-ramp for struggling biotechs buff.ly/n7UACI1

Prasad to oversee @US_FDA Commissioners Priority Voucher Program; his role among handful of new details on pilot program buff.ly/ecTW5r2

With a CRL disclosed Tuesday, Replimune became the latest biotech to say an FDA review decision conflicted with the signals the agency had been sending under prior leadership buff.ly/Gi2BYD1

BioCentury's latest biopharma Management Moves: Steve Bates, longtime head of BIA, named executive chair of U.K.’s Office of Life Sciences. Plus: Novartis names Mazuk chief patient experience officer and updates from Seres and ABPI buff.ly/uKaVtvY

Sanofi is buying vaccine technology company Vicebio for $1.15B up front, soon after the emergence of early data from a clinical study of the start-up's first product buff.ly/LxK8gyY

BioCentury's latest management moves column: Nodthera names Jyothis George CMO. Plus: Updates from Protalix, Medigene buff.ly/0dyic9y

New @US_FDA CDER Director Tidmarsh is taking over an agency in crisis. The media will focus on his controversial COVID comments, but industry wants to know if he can right the ship. buff.ly/ScS9MVU

As @Sarepta loses platform designation, the @US_FDA pathway’s future is uncertain. #GeneTherapy #FDA $SRPT buff.ly/N1OG1EB

.@US_FDA Commissioner Makary says he is convinced an mRNA vaccine killed friend's father. Will his embrace of anecdotal evidence extend beyond COVID? buff.ly/j3HmkfK

Another Jessie Gelsinger moment for gene therapy? FDA, industry and patient groups should come together to learn the lessons from tragic, avoidable deaths from Sarepta’s gene therapies buff.ly/T7d6YtE

Cueing up quantum computing in biopharma. Biopharma is full of the types of problems where the still-nascent technology is expected to excel buff.ly/xKDCUeV

Capital flows continue in Asia. Ascentage Pharma raises $192M in Hong Kong placement while Korea-based Illimis raises $42 million in a series B round: BioCentury's latest Finance Report buff.ly/Q8Qm5ab

Seed/Series A money up in 1H25, but mostly a few companies raising monster rounds: a BioCentury Data Byte buff.ly/lIgCs1G

Rare win in women's health from Diamedica, among tiny preeclampsia pipeline buff.ly/EaYO29I

Novartis names Mehta new CFO. Plus: Biontech’s chief strategy officer steps down, and updates from Vor, Vivid Dx, in BioCentury's Management Tracks buff.ly/fju5gdE

U.K.’s new life sciences strategy has big ambitions — can they be met? More investment, faster trials, and better data access headline a renewed push to elevate the U.K. life sciences sector buff.ly/Th8cWPM

Third patient dies from acute liver failure caused by a Sarepta gene therapy buff.ly/G0IbXHh

Draig names Doug Williams chair. Plus new leadership at Puretech, Synendos, and more, in BioCentury's Management Tracks buff.ly/x2zNyCi

Science Spotlight: Targeting VISTA to improve radiotherapy. BioCentury’s translational roundup also includes a new glycosylation enzyme, a multi-modal vaccine strategy, and nine papers with links to neurology companies buff.ly/5T6QulL

Biotech venture financing fell in 1H25, both in dollars raised and number of rounds: a BioCentury Data Byte buff.ly/sXrOWjf